Skip to main content
BeNeLuxA

Hauptnavigation

  • News
    • Belgium and the Netherlands opt for individual negotiations after a joint assessment of gene therapy Hemgenix®
    • Steering Committee Meeting of the Beneluxa initiative
    • The Beneluxa iniative identified thirteen impactful medicines suitable for joint HTA submission
    • Archive
  • About
    • Beneluxa initiative
    • Mandate and organisation
    • Benefits
  • Statements
  • Activities
    • Horizon Scanning
    • Health Technology Assessment
      • HTA procedures within the Beneluxa Initiative
    • Information Sharing
      • Patient registries
    • Pricing and reimbursement
  • Documents
    • Background documents
    • Publications
    • Press releases
    • Templates
  • Contact
  • xclose

Zweite Menüebene Hauptnavigation

  • Belgium and the Netherlands opt for individual negotiations after a joint assessment of gene therapy Hemgenix®
  • Steering Committee Meeting of the Beneluxa initiative
  • The Beneluxa iniative identified thirteen impactful medicines suitable for joint HTA submission
  • Archive
  • xclose

News

Contact

info@beneluxa.org

Info

Disclaimer

Links

About

Back to top